Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04629248
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Active, not recruiting
Phase Phase 3
Start date June 25, 2021
Completion date December 29, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05800873 - Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 Phase 1
Recruiting NCT05514015 - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy Phase 4
Recruiting NCT05668403 - A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy Phase 1
Recruiting NCT05696613 - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy Phase 3
Recruiting NCT05862233 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 3
Not yet recruiting NCT06466135 - Study of WAL0921 in Patients With Glomerular Kidney Diseases Phase 2
Not yet recruiting NCT06120673 - REmission in Membranous Nephropathy International Trial (REMIT) Phase 3
Recruiting NCT05398653 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 1/Phase 2
Active, not recruiting NCT05136456 - Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy Phase 2
Recruiting NCT05707377 - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy Phase 2/Phase 3